Savara Inc
YB4P
Company Profile
Business description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Contact
1717 Langhorne Newtown Road
Suite 300
LanghornePA19047
USAT: +1 512 614-1848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,770.60 | 25.40 | -0.29% |
CAC 40 | 7,684.68 | 80.43 | -1.04% |
DAX 40 | 23,516.23 | 255.22 | -1.07% |
Dow JONES (US) | 42,586.59 | 381.03 | -0.89% |
FTSE 100 | 8,850.63 | 34.29 | -0.39% |
HKSE | 23,892.56 | 142.82 | -0.59% |
NASDAQ | 19,585.60 | 76.88 | -0.39% |
Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
S&P 500 | 6,025.26 | 20.00 | -0.33% |
S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
SSE Composite Index | 3,377.00 | 25.66 | -0.75% |